

Associations between hypothalamic–pituitary–adrenal axis function and peak bone mass at 20 years of age in a birth cohort

Kun Zhu^{1,2}, David Henley^{1,2}, Craig Pennell³, Carly E Herbison³, Jenny Mountain⁴,
Stephen Lye⁵, John P Walsh^{1,2}

¹Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Australia;

²School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia;

³School of Women's and Infants' Health, University of Western Australia, Crawley, Australia;

⁴School of Population Health, University of Western Australia, Crawley, Australia;

⁵Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada

Corresponding author: Kun Zhu, PhD, Department of Endocrinology and Diabetes, Sir Charles Gardiner Hospital, Nedlands, WA 6009, Australia; Email: kun.zhu@uwa.edu.au; Phone: +61 8 9346 4969; Fax: +61 8 9346 4109

Key words: hypothalamic-pituitary-adrenal axis function; Trier Social Stress Test; peak bone mass; young adults; Raine study

Abbreviations: AUC, area under the curve; BMI, body mass index; BMD, bone mineral content; BMD, bone mineral density; CV, coefficient of variation; DXA, dual-energy x-ray absorptiometry; HPA, hypothalamic-pituitary-adrenal; TSST, Trier Social Stress Test

1 **Abstract**

2 In older adults, high-normal circulating cortisol levels are associated with lower bone mass,
3 but relationships between hypothalamic-pituitary-adrenal axis function and peak bone mass
4 in young adults have not been examined. We studied 411 male and 390 female participants in
5 the Western Australia Pregnancy Cohort (Raine) Study. At 18 years of age, participants
6 underwent a Trier Social Stress Test (TSST) with measurement of plasma and salivary
7 cortisol at baseline and at multiple time points after stress. Cortisol responses were classified
8 as anticipatory responder (significant fall in cortisol during the test), reactive responder
9 (significant increase) or non-responder. At 20 years, total body bone mineral content (BMC)
10 and density (BMD) were measured by DXA. In males, after adjustment for weight, height
11 (for BMC and bone area only), alcohol and smoking, there was a significant inverse
12 relationship between both plasma and salivary cortisol measured at baseline in the TSST and
13 each of BMC and BMD, such that each additional 10% of salivary cortisol was associated
14 with reductions of 6.9 g (95% CI -11.7, -2.2) in BMC, and 1.8 mg/cm² (95% CI -3.3, -0.4) in
15 BMD. Males classified as anticipatory responders in the TSST had 3.2% lower BMC
16 (adjusted mean ± SE: 3131 ± 28 vs. 3233 ± 18 g, P=0.006) and 2.5% lower BMD (1108 ± 9
17 vs. 1136 ± 6 mg/cm², P=0.022) than reactive responders. In females, there were no significant
18 relationships between baseline cortisol or TSST responses and BMC or BMD in covariate-
19 adjusted analyses. We conclude that in young males (but not females), higher circulating
20 cortisol at the baseline of the stress test and an anticipatory responder pattern on the TSST are
21 associated with lower total body bone mass.

22 **Introduction**

23 It is well-recognized that glucocorticoid treatment is a risk factor for osteoporosis (1), and
24 excessive endogenous cortisol production in Cushing’s syndrome leads to significant
25 reduction in bone mineral density (BMD) and increased fracture risk (2). Less is known on
26 the effects of endogenous cortisol within the physiological range on bone health, but there is
27 evidence from epidemiological studies in older adults that high-normal cortisol levels may be
28 associated with lower BMD (3-6) or increased rate of bone loss (3, 7).

29

30 Analysis of the relationships between endogenous cortisol and bone health is challenging
31 because of the complexity of hypothalamic–pituitary–adrenal (HPA) axis physiology,
32 including diurnal variation, stress responses, and interactions between obesity and cortisol
33 secretion and metabolism. In previous studies of older adults, a range of measures of HPA
34 axis function have been used, including integrated 24-hour cortisol level and trough cortisol
35 concentration (3), morning and evening salivary cortisol levels (4), post-dexamethasone
36 cortisol level (5, 6), and peak plasma cortisol following tetracosactrin stimulation (7). The
37 Trier Social Stress Test (TSST), a psychosocial stress protocol, has been shown to reliably
38 and consistently produce HPA axis stimulation and elicit the highest endocrine responses of
39 any laboratory stressor (8, 9), therefore may be more physiologically relevant than
40 pharmacological stressors in the evaluation of HPA axis activity. However, the association
41 between the HPA axis response to TSST and bone density has not been studied. In addition,
42 there have been no studies examining the relationships between HPA axis function and peak
43 bone mass in young adults. This is potentially important, as attainment of optimal peak bone
44 mass in early adult life is considered the best protection against osteoporosis in later life (10).

45

46 In the Western Australia Pregnancy Cohort Study, a well-characterized community-based
47 cohort study, HPA axis function was evaluated by the Trier Social Stress Test at late
48 adolescence (18 years of age). In this analysis, we examined relationships between HPA
49 function at late adolescence and bone mass measured at 20 years of age in participants, when
50 peak bone mass is generally attained (11).

51 **Subjects and methods**

52 *Subjects*

53 The study participants were from the Western Australian Pregnancy Cohort (Raine) Study,
54 which recruited 2,900 pregnant women from the public antenatal clinic at King Edward
55 Memorial Hospital and surrounding private clinics in Perth, Western Australia between May
56 1989 and November 1991, and has subsequently followed the offspring as a birth cohort
57 study. Inclusion criteria were a gestational age between 16 and 20 weeks, English language
58 skills sufficient to understand the study demands, an expectation to deliver at King Edward
59 Memorial Hospital, and an intention to remain in Western Australia to enable future follow-
60 up of their child (12). Compared with the general Western Australian population, the Raine
61 cohort at birth was characterized by higher proportions of high-risk births and fathers
62 employed in managerial and professional positions, but comparison of participants remaining
63 in the study at the 14-year follow-up suggested attrition resulted in a cohort comparable with
64 the general population (13). Of the 2,868 children born, 1,306 participated in the physical
65 examination component of the 20-year cohort follow-up, of whom 1,183 had valid whole
66 body dual-energy x-ray absorptiometry (DXA) scans (14). Of these, 872 underwent the TSST
67 at 18 years. Excluding 24 participants who were taking medications such as exogenous
68 steroids, neuroactive or anti-depressant medications at the time of TSST, 33 participants who
69 did not complete the test or had diurnal disturbances (worked night shifts or had little sleep),
70 and 14 participants displayed unusual patterns which could not be categorized (it was unclear
71 if this was due to physiological or technical reasons), data from 411 males and 390 females
72 were included in this analysis (**Figure 1**). The study at both 18 and 20 years of age was
73 approved by the Human Research Ethics Committee of University of Western Australia.
74 Written informed consent was obtained from each participant.

75

76 ***Trier Social Stress Test (TSST)***

77 A TSST was conducted at the 18-year follow-up visit. Participants were instructed to refrain
78 from physical exercise, smoking, medication, eating and drinking anything besides water for
79 one hour before the test, which was conducted in the afternoon between 1200h and 1600h.
80 This time of day was selected in order to minimise the effect of HPA axis circadian
81 rhythmicity on the results. Prior to the test, participants completed a questionnaire regarding
82 current medication use, smoking habits, and oral contraceptive use. An intravenous cannula
83 was inserted into a forearm vein under local anaesthesia for blood sampling, and participants
84 then rested for 45 minutes before starting the test. The test itself took 15 minutes to complete
85 and consisted of a free speech interview and an arithmetic task facing a non-responsive
86 audience and a dummy camera according to established protocols (15, 16). Blood samples
87 were taken for plasma total cortisol levels just prior to the test (baseline, 0 minutes), after
88 completing the test (15 minutes) and then at 25, 35, 45, 60, 75 and 105 minutes. Saliva
89 samples were collected using Salivette collection devices (Sarstedt, Germany) from all
90 participants at 0, 15, 35 and 105 minutes. In addition, for the 153 participants (99 females)
91 who elected not to have blood sampling, saliva were collected at all eight time points as for
92 the schedule for blood collection. No formal assessment for gum disease was made, but
93 bleeding from gum disease would significantly increase salivary cortisol levels from
94 contamination with blood, resulting in a clear outlier and exclusion from the analysis. Time
95 zero was reported as the start of the TSST as per the standard protocol (15). All biological
96 samples were kept on ice during the test, then centrifuged, aliquoted and frozen at -80°C until
97 assayed. For plasma and salivary cortisol, area under the curve above baseline with respect to
98 increase (AUC_I) was calculated using the trapezoidal rule (17); this parameter has been
99 shown by principal components analysis to emphasize changes in cortisol profile over time
100 (18).

101

102 TSST responses were categorised into three patterns: reactive responder, anticipatory
103 responder and non-responder, in alignment with previous reports of distinct response patterns
104 in the literature (19, 20). The primary parameter used for stress pattern determination was the
105 plasma total cortisol measured at eight regularly spaced time points. Additional information
106 was derived from the secondary parameter of salivary cortisol. For participants who only had
107 salivary cortisol measured, the stress pattern was determined from the salivary cortisol
108 recorded at eight time points. A set of criteria for the grouping of TSST patterns was
109 developed and refined from examination of the literature and response data, and the method
110 has been described in detail elsewhere (21). In brief, reactive responders were defined as
111 having an increase in cortisol from baseline of greater than twice of the CV of the cortisol
112 assays (22), in this case 13.2% for the plasma and 9.04% for the salivary cortisol assay.
113 Anticipatory responders were defined as exhibiting a drop from baseline within the first 60
114 minutes of greater than twice the CV plus an estimation of afternoon cortisol changes due to
115 diurnal variation (21) . Non-responders did not show reactive or anticipatory responses. The
116 proportion of participants in each response pattern did not differ significantly between those
117 with saliva samples only and those with both blood and salivary samples (males $P = 0.450$;
118 females $P = 0.239$).

119

120 *Laboratory assays*

121 Plasma total cortisol and salivary free cortisol were quantified using the GammaCoatTM ¹²⁵I
122 cortisol radioimmunoassay kit (DiaSorin, Stillwater, MN, USA). All the samples from the
123 same participant were analysed within the same assay. The inter-assay CV for plasma and
124 salivary cortisol were 6.6% and 4.5% respectively, and the intra-assay CV were <10%. The
125 sensitivity of the assay was 5.8 nM for total plasma cortisol and 0.3 nM for salivary cortisol.

126 The assay is highly specific for cortisol with minimal cross-reactivity (~1%) with other
127 endogenous corticosteroids. All samples were assayed in duplicate against an appropriate
128 standard curve and were repeated with additional dilutions, where required.

129

130 ***Whole body DXA***

131 Whole body DXA was performed at the 20-year follow-up visit using on a Norland XR-36
132 densitometer (Norland Medical Systems, Inc., Fort Atkinson, WI, USA), according to
133 manufacturer-recommended procedures. Analysis of scans was performed using built-in
134 machine software (version 4.3.0) and all analyses were checked by one researcher (JM) for
135 consistency. The analysis provided estimates of whole body bone mineral content (BMC) (g),
136 bone area (cm²) and areal BMD (mg/cm²). The densitometer had a variation in precision of
137 <2.0% for the measured site at standard speed.

138

139 ***Other assessments***

140 Weight and height were measured with subjects dressed in light clothes at 18 and 20 years.
141 Body mass index (BMI) was calculated as weight (kg)/height (m)². Information on smoking
142 habit at 18 and 20 years, and contraceptive use (females only) at 18 years was collected using
143 questionnaires. A validated semi-quantitative food frequency questionnaire from the Cancer
144 Council Victoria (23) was used to assess dietary intake including calcium and alcohol intake
145 at 20 years. Physical activity level at 20 years was assessed using the International Physical
146 Activity Questionnaire (IPAQ), and categorised as low, medium and high according to the
147 IPAQ scoring protocol (24).

148

149 ***Data analysis***

150 Variables are presented as mean (SD) for each sex unless otherwise stated. The normality of
151 continuous variables was checked through the construction of histograms. Baseline plasma
152 and salivary cortisol were logarithmically transformed prior to analysis as they exhibited a
153 skewed distribution. Comparisons between males and females were made by Student t-test or
154 chi-square test as appropriate. The associations of baseline cortisol, as well as AUC₁ and
155 TSST response patterns (derived from data at multiple time points) with bone measures were
156 evaluated in males and females separately. Correlation coefficients between baseline cortisol
157 and bone measures were calculated using Pearson's correlation analysis in males, and in
158 females the partial correlations were calculated accounting for oral contraceptive use. These
159 associations were further evaluated using linear regression models with bone measures as
160 dependent variables, baseline cortisol or AUC₁ as predictor variables, and incorporating the
161 following covariates: weight and alcohol consumption at 20 years, and smoking at 18 and 20
162 years, which were chosen based on evidence of the influence of lifestyle factors on bone
163 health (25). Age was not adjusted for in the models due to the narrow age range of the study
164 participants. Height at 20 years was adjusted in the models for total body BMC and bone area
165 as it is highly correlated with these two variables. Results were further adjusted for calcium
166 intake and physical activity at 20 years for participants with these data available. To account
167 for the inter-correlation between predictor variables, the semi-partial R² for each predictor
168 variable was calculated to estimate the proportion of the variance associated uniquely with
169 each predictor. Collinearity was tested in each regression model, and a variance inflation
170 factor (VIF) value larger than 10 was considered as showing the existence of collinearity or
171 near collinearity (26). Collinearity was not observed in any of the models. Comparisons
172 between the three TSST response categories were made by analysis of variance (ANOVA)
173 with Tukey's HSD post hoc test or chi-square test in each sex. Comparisons between bone
174 measures in these three groups were made by analysis of covariance (ANCOVA) adjusting

175 for the covariates listed above with Bonferroni post hoc test. There were significant
176 interactions between sex and predictor variables (HPA measures) on the outcome measures
177 and we elected to analyse data from males and females separately. Women taking oral
178 contraceptives had higher plasma cortisol concentrations and lower total body BMD than
179 women not taking them, but the interaction terms for oral contraceptive use and predictor
180 variables were not significant for any outcome measures, indicating that the relationships
181 between HPA measures and bone were not significantly altered by contraceptive use. We
182 thus included oral contraceptive treatment as a covariate in the analysis in females, but did
183 not analyse subgroups of women according to contraceptive use. Statistical significance level
184 was set at $P < 0.05$ (two-tailed). All analyses were performed using IBM SPSS (version 21,
185 IBM, Chicago, IL, USA).

186 **Results**

187 *Characteristics of participants*

188 The mean age (SD) of participants at the time of the TSST was 18.3 (0.3) years and at time of
189 DXA scanning was 20.0 (0.4) years. At 18 and 20 years, there were no significant differences
190 between male and female participants in age and BMI, but males were taller and heavier and
191 more likely to smoke (**Table 1 & 2**). At 18 years, the baseline mean plasma cortisol level was
192 lower in males than in females, but there was no significant sex difference in peak plasma
193 cortisol. Salivary cortisol was significantly higher in males compared with females for both
194 baseline and peak levels. The higher baseline total plasma cortisol levels in females were
195 mainly due to the high levels in those on oral contraceptive (565.9 ± 265.6 nM), as estrogen
196 increases corticosteroid-binding globulin levels (27). Males actually had higher total plasma
197 cortisol levels than females not on oral contraceptive (375.5 ± 177.1 vs 309.6 ± 141.8 nM,
198 $P < 0.001$), and higher salivary cortisol levels than females either on oral contraceptive or not
199 (15.3 ± 10.3 vs 13.2 ± 10.4 and 12.3 ± 7.3 nM, both $P < 0.05$). There were no significant sex
200 differences in AUC_1 for either plasma or salivary cortisol (Table 1). At 20 years, compared to
201 females, males had significantly higher calcium and alcohol intake, physical activity level,
202 and total body BMC, bone area and BMD (Table 2).

203

204 *TSST baseline cortisol and bone mass*

205 In males, plasma and salivary cortisol measured at TSST baseline each showed a weak
206 negative correlation with total body BMC ($r: -0.135$ and -0.124 , respectively, both $P < 0.05$)
207 and BMD ($r: -0.146$ and -0.132 , respectively, both $P < 0.01$) but no significant correlation with
208 bone area. In addition, the AUC_1 for both plasma and salivary cortisol had a significant
209 positive correlation with total body BMD ($r: 0.106$ and 0.126 , respectively, both $P < 0.05$). In
210 females, there was a weak negative partial correlation (after accounting for oral contraceptive

211 use) between baseline plasma cortisol and each of total body BMC (r: -0.133, P<0.05) and
212 bone area (r: -0.187, P<0.01) but not BMD. There were no significant correlations between
213 salivary cortisol or AUC₁ for either plasma or salivary cortisol and any bone measures in
214 females.

215
216 In males, after adjustment for relevant covariates, the inverse relationships between baseline
217 plasma and salivary cortisol and each of total body BMC and BMD, and the positive
218 relationship between AUC₁ for salivary cortisol and total body BMD remained significant
219 (**Table 3**). In addition, AUC₁ for salivary cortisol showed a positive relationship with total
220 body BMC after the adjustment of covariates (Table 3). In females, only the negative
221 association between total plasma cortisol and total body bone area remained significant after
222 covariate adjustment. Based on the regression coefficients of log-transformed predictor
223 variables, we estimate that in males, each additional 10% of baseline plasma cortisol was
224 associated with reductions of 6.8 g (95% CI -13.2, -0.3) in total body BMC and 2.2 mg/cm²
225 (95% CI -4.2, -0.2) in total body BMD, whereas each additional 10% of salivary cortisol was
226 associated with reductions of 6.9 g (95% CI -11.7, -2.2) in total body BMC, and 1.8 mg/cm²
227 (95% CI -3.3, -0.4) in total body BMD. In females, each additional 10% increase in total
228 plasma cortisol at baseline was associated with a reduction of 3.1 cm² (95% CI -5.8, -0.3) in
229 total body bone area. When physical activity level and calcium intake were further adjusted
230 for in subjects with these data available (298 males and 337 females), results were essentially
231 unchanged, except the associations between AUC₁ for total plasma cortisol and total body
232 BMC and BMD became significant in males (β 3.5, 95% CI 0.4-6.7, P = 0.029 and β 1.0, 95%
233 CI 0.02-1.9, P = 0.046, respectively).

234

235 In males, baseline total plasma and salivary cortisol uniquely associated with 0.8% to 1.7% of
236 the variance in total body BMC and BMD (semi-partial R^2 0.008 – 0.017), which is higher
237 than the variance uniquely associated with calcium intake for total body BMC (0.6-0.8%).
238 Physical activity level was not a significant predictor of bone measures in any models.

239

240 *Analyses by TSST response pattern*

241 The percentages of participants in the three TSST response groups – reactive responder,
242 anticipatory responder and non-responder – were 63.3, 24.6 and 12.1% for males and 51.3,
243 29.5 and 19.2% for females, respectively, a significant sex difference ($P=0.001$). In both
244 genders, there were no significant differences between the three TSST response patterns in
245 anthropometric and lifestyle characteristics, except for female non-responders, who had
246 significantly lower body weight and BMI than reactive responder group at both age 18 and 20
247 years (Tables 1 & 2). As expected, in both genders baseline plasma and salivary cortisol were
248 significantly higher in anticipatory responder than the other two groups, whereas peak plasma
249 cortisol was higher in reactive responders and anticipatory responders than non-responders.
250 The AUC_I for both plasma and salivary cortisol were highest in reactive responders, and
251 lowest in anticipatory responders (Table 1).

252

253 In males, in the unadjusted analysis, total body BMC and BMD were significantly lower in
254 anticipatory responders compared to reactive responders, with no significant differences
255 between non-responders and the other groups (Table 2). After adjustment for relevant
256 covariates, the differences remained significant, such that total body BMC was 3.2% lower
257 ($P=0.006$) and BMD 2.5% lower ($P=0.022$) in the anticipatory responder group than in the
258 reactive responder group (**Table 4**).

259 In females, in the unadjusted analysis, non-responders had significantly lower total body
260 BMD than reactive responders (Table 2), but the significance did not remain after covariate
261 adjustment (Table 4). In both males and females, results were essentially unchanged after
262 further adjustment for physical activity level and calcium intake in subjects with these data
263 available (data not shown).

264 **Discussion**

265 In this study of young adults, we found that in males, plasma and salivary cortisol measured
266 at 18 years of age at the baseline of a well-validated stress test had a negative association
267 with total body BMC and BMD measured at 20 years, independent of body weight, alcohol
268 intake, smoking status, calcium intake and physical activity level. Males classified as
269 anticipatory responders (characterized by high pre-test cortisol levels which fell after stress)
270 had 3.2% lower total body BMC and 2.5% lower total body BMD than reactive responders
271 (who had lower pre-test cortisol levels which increased after stress). In females, however,
272 there were no significant relationships between cortisol or TSST responses and BMC or
273 BMD in covariate-adjusted analyses. These results suggest that in males (but not females),
274 endogenous cortisol secretion and its response to stressful stimuli may be one of the factors
275 contributing to peak bone mass. Since a 5% difference in BMD is associated with a 20%
276 difference in the risk of osteoporotic fracture and a 50% difference in the risk of hip fracture
277 (28), the magnitude of the differences observed may be clinically relevant, with implications
278 for the fracture risk in later life.

279

280 An association between endogenous cortisol and peak bone mass is biologically plausible,
281 since excess exogenous or endogenous glucocorticoids as in Cushing's syndrome leads to a
282 reduction in bone mass and quality, and increased fracture risk (29). Our results are consistent
283 with a small number of observational studies in older adults, in which high-normal
284 glucocorticoid levels within the physiological range are associated with reduced bone density
285 in cross-sectional analysis, and accelerated bone loss during follow-up (3-7). These studies
286 have generally been interpreted as indicating that endogenous glucocorticoids contribute to
287 age-related bone loss. Our study extends these findings to young adults and suggests that as
288 well as contributing to bone loss in the elderly, endogenous glucocorticoid secretion and its

289 response to stressful stimuli may affect attainment of peak bone mass. Dual roles of
290 endogenous glucocorticoids during development and aging are biologically plausible, since
291 serum cortisol is a heritable trait (with heritability estimates of up to 60%) (30, 31), which
292 demonstrates considerable intra-individual reproducibility on repeated sampling over time
293 (32); thus an individual with high-normal cortisol levels in childhood is likely to have high-
294 normal levels in later life. Our study assessed total cortisol in plasma samples, where the
295 majority of cortisol is bound to cortisol binding globulin and albumin, and salivary cortisol
296 which reflects free cortisol. Biological activity may depend more upon free cortisol, as
297 concentrations of carrier proteins have been reported to vary between and within individuals
298 depending on factors including oestrogen status and posture (27, 33). These factors and the
299 greater number of subjects with salivary samples may explain the stronger association of
300 salivary cortisol with total body BMC and BMC compared with plasma total cortisol.

301

302 In the TSST, the majority of participants were classified as reactive responders,
303 demonstrating a dynamic HPA response to stress. Anticipatory responders appeared to be
304 “pre-stressed” before the TSST, with significantly higher baseline cortisol levels than reactive
305 responders and non-responders. We speculate that anticipatory responders have a subtle but
306 significant chronic excess in cortisol exposure compared with reactive responders, which may
307 contribute to the lower bone mass seen in males in this group, as increased circulating
308 glucocorticoids could cause the apoptosis of osteoblasts and reduce their activity and increase
309 the activity of osteoclasts (2). In contrast to the negative association between baseline cortisol
310 and bone mass, AUC_1 for salivary cortisol during the TSST was positively associated with
311 BMC and BMD in men, and there were similar trends (although not statistically significant)
312 for plasma cortisol. This positive relationship between a measure of cortisol secretion and
313 bone mass appears paradoxical. The normal HPA axis is in a state of dynamic equilibrium

314 and different patterns of glucocorticoid presentation exert different responses which are tissue
315 specific (34), and it is conceivable that normal HPA activity in some way exerts a positive
316 influence on bone health. Consistent with this, in a study of premenopausal women, there was
317 a positive relationship between salivary peak cortisol after awakening and bone mass
318 assessed by calcaneal ultrasound (35). It is also possible, however, that higher AUC₁ and
319 higher bone mass are each indicators of better general health, with no causal relationship
320 between the two. In non-responders, pre-test cortisol levels were comparable to reactive
321 responders but AUC₁ was significantly lower. Despite these differences in cortisol profile,
322 bone mass did not differ significantly between non-responders and the other two groups. The
323 reason for this is uncertain and warrants further study.

324

325 While it would be difficult to modify endogenous cortisol, optimising early life factors might
326 benefit HPA axis function, and thus the development of peak bone mass. In animal studies,
327 protein restriction during mid- and late pregnancy is associated with reduced methylation of
328 key CpG-rich islands in the promoter region of the glucocorticoid receptor (GR) gene,
329 resulting in increased GR expression and features of hypercortisolism (36). Maternal stress
330 during pregnancy is known to influence the developing HPA axis in the foetus (37).

331

332 In females, baseline plasma cortisol showed a negative relationship with total body BMC and
333 bone area in the unadjusted analysis, but after adjustment for covariates, only the negative
334 correlation with bone area remained significant. Non-responders had significantly lower total
335 body BMD than reactive responders in unadjusted analysis, but that was no longer significant
336 after the low body weight of non-responders had been accounted for. The basis for the sex
337 difference in the results of our study is not clear, but it is consistent with other reports of sex
338 differences in the cortisol-bone relationship. For example, in mice, endogenous

339 glucocorticoid signalling is required for normal bone structure, growth, and strength in
340 females but not males (38). In a study of Chinese people, a common variant in GR was
341 associated with extreme BMD in men but not women (39), and in a cohort study of healthy
342 older individuals, an association between baseline urinary free cortisol and incident fracture
343 was more apparent in men than in women (40). *In vitro*, cortisol has sex-specific effects on
344 activity of the enzyme aromatase P450 (which converts testosterone to estradiol), stimulating
345 aromatase in subcutaneous preadipocytes prepared from women, but inhibiting its activity in
346 preadipocytes prepared from men (41). Since estradiol has a positive effect on bone mass in
347 both men and women (42), this provides a possible basis for a sex difference in the effect of
348 cortisol on bone, although it is important to note that effects of cortisol on aromatase activity
349 in bone tissue have not been studied.

350

351 In the present study, we used TSST baseline plasma and salivary cortisol levels, AUC₁ during
352 the test, and TSST response pattern to evaluate the relationship. This has the advantage of
353 providing a pre-test measure of HPA axis function, increase of cortisol in response to stress
354 and a response to a social stress. Other strengths of the study include the large sample size,
355 detailed analysis of the TSST response patterns, and assessment of bone mass at skeletal
356 maturity. Our study also has limitations. Firstly, its observational, cross-sectional nature
357 means we cannot assume that the relationships between cortisol and bone are causal.
358 Although we adjusted for several important confounding variables, the significant
359 associations observed may still be due to potential residual or uncontrolled confounders.
360 Secondly, most of the participants were Caucasian, and the study findings may not be
361 applicable to other ethnic groups. Thirdly, the DXA scans were performed two years later
362 after the TSST. However, since intra-individual variation in plasma cortisol is less than inter-
363 individual variation over time, and biological effects of endogenous cortisol on bone are

364 likely to be long term, this should not be a significant confounder. Longitudinal studies (1.5-
365 6 years) with repeated measures of cortisol levels and circadian rhythm (43) and cortisol
366 reactivity at the laboratory challenge (44) in children and adolescence have shown relative
367 stability of HPA activity across time. Another limitation is that we did not measure BMD at
368 fracture relevant sites such as spine and hip. Nevertheless, previous studies have shown a
369 close relationship between BMD measures of total body, lumbar spine and hip (45), and the
370 value of total body BMD in predicting hip fracture (46).

371

372 In conclusion, in young males, but not females, high circulating cortisol at the baseline of a
373 social stress test, smaller area under the curve during the test and therefore an anticipatory
374 responder TSST pattern are associated with lower total body BMC and BMD. Understanding
375 the role of endogenous cortisol levels on bone physiology may be of value in promoting
376 optimal peak bone mass development in young adults.

377 **Acknowledgments**

378 We gratefully acknowledge the efforts of the Raine Study participants, the Raine Study team
379 for study co-ordination and data collection and Dr Anke Van Eekelen for conducting the
380 TSST testing.

381

382 **Funding support**

383 Core funding for the Raine Study is provided by The University of Western Australia (UWA),
384 Telethon Kids Institute, Raine Medical Research Foundation, UWA Faculty of Medicine,
385 Dentistry and Health Sciences, Women's and Infant's Research Foundation, Curtin
386 University and Edith Cowan University. The 20 year cohort follow up assessment was funded
387 by project grants from the Australian National Health and Medical Research Council and
388 funding from the Lions Eye Institute, Nedlands, Western Australia. The Canadian Institutes
389 of Health Research funded the TSST and DXA data collection (CIHR, Lye et al, MOP-
390 82893).

391

392 **Author's disclosure:** Kun Zhu, David Henley, Craig Pennell, Carly E Herbison, Jenny
393 Mountain, Stephen Lye and John P Walsh declare that they have no conflict of interest.

References

1. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. *Endocrinol Metab Clin North Am.* 2012;41(3):595-611.
2. Hardy R, Cooper MS. Adrenal gland and bone. *Arch Biochem Biophys.* 2010;503(1):137-45.
3. Dennison E, Hindmarsh P, Fall C, Kellingray S, Barker D, Phillips D, et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. *J Clin Endocrinol Metab.* 1999;84(9):3058-63.
4. Raff H, Raff JL, Duthie EH, Wilson CR, Sasse EA, Rudman I, et al. Elevated salivary cortisol in the evening in healthy elderly men and women: correlation with bone mineral density. *J Gerontol A Biol Sci Med Sci.* 1999;54(9):M479-83.
5. Kann P, Laudes M, Piepkorn B, Heintz A, Beyer J. Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. *Clin Rheumatol.* 2001;20(1):25-9.
6. Siggelkow H, Etmanski M, Bozkurt S, Grobeta P, Koepp R, Brockmoller J, et al. Genetic polymorphisms in 11beta-hydroxysteroid dehydrogenase type 1 correlate with the postdexamethasone cortisol levels and bone mineral density in patients evaluated for osteoporosis. *J Clin Endocrinol Metab.* 2014;99(2):E293-302.
7. Reynolds RM, Dennison EM, Walker BR, Syddall HE, Wood PJ, Andrew R, et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. *Calcif Tissue Int.* 2005;77(3):134-8.
8. Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. *Psychol Bull.* 2004;130(3):355-91.
9. Foley P, Kirschbaum C. Human hypothalamus-pituitary-adrenal axis responses to acute psychosocial stress in laboratory settings. *Neurosci Biobehav Rev.* 2010;35(1):91-6.
10. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, et al. Peak bone mass. *Osteoporos Int.* 2000;11(12):985-1009.
11. Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. *J Bone Miner Res.* 2011;26(8):1729-39.
12. Newnham JP, Evans SF, Michael CA, Stanley FJ, Landau LI. Effects of frequent ultrasound during pregnancy: a randomised controlled trial. *Lancet.* 1993;342(8876):887-91.
13. Robinson M, Oddy WH, McLean NJ, Jacoby P, Pennell CE, de Klerk NH, et al. Low-moderate prenatal alcohol exposure and risk to child behavioural development: a prospective cohort study. *BJOG.* 2010;117(9):1139-50.
14. Zhu K, Briffa K, Smith A, Mountain J, Briggs AM, Lye S, et al. Gender differences in the relationships between lean body mass, fat mass and peak bone mass in young adults. *Osteoporos Int.* 2014;25(5):1563-70.
15. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. *Neuropsychobiology.* 1993;28(1-2):76-81.
16. Kudielka BM, Wüst S, Kirschbaum C, Hellhammer DH. Trier Social Stress Test. In: Fink E-i-CG, ed. *Encyclopedia of Stress (Second Edition)*. New York: Academic Press; 2007:776-81.
17. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone

- concentration versus time-dependent change. *Psychoneuroendocrinology*. 2003;28(7):916-31.
18. Fekedulegn DB, Andrew ME, Burchfiel CM, Violanti JM, Hartley TA, Charles LE, et al. Area under the curve and other summary indicators of repeated waking cortisol measurements. *Psychosom Med*. 2007;69(7):651-9.
 19. Schommer NC, Hellhammer DH, Kirschbaum C. Dissociation between reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress. *Psychosom Med*. 2003;65(3):450-60.
 20. Engert V, Efanov SI, Duchesne A, Vogel S, Corbo V, Pruessner JC. Differentiating anticipatory from reactive cortisol responses to psychosocial stress. *Psychoneuroendocrinology*. 2013;38(8):1328-37.
 21. Herbison CE, Henley D, Marsh J, Atkinson H, Newnham J, Matthews S, et al. Characterisation and novel analyses of acute stress response patterns in a population based cohort of young adults: influence of gender, smoking and BMI. *Stress*. 2016; in press.
 22. Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. *N Engl J Med*. 1985;312(21):1343-9.
 23. Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G. The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. *Aust N Z J Public Health*. 2000;24(6):576-83.
 24. IPAQ. <http://www.ipaq.ki.se/scoring.htm>.
 25. Zhu K, Prince RL. Lifestyle and osteoporosis. *Curr Osteoporos Rep*. 2015;13(1):52-9.
 26. Kleinbaum DG, Kupper L, L. , Muller KE, Nizam A. *Applied Regression Analysis and other Multivariable Methods*. Pacific Grove, USA: Duxbury Press; 1998.
 27. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. *Contraception*. 1990;41(4):345-52.
 28. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. *J Bone Miner Res*. 2005;20(7):1185-94.
 29. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int*. 2002;13(10):777-87.
 30. Gustafsson PA, Gustafsson PE, Anckarsater H, Lichtenstein P, Ljung T, Nelson N, et al. Heritability of cortisol regulation in children. *Twin Res Hum Genet*. 2011;14(6):553-61.
 31. Bartels M, Van den Berg M, Sluyter F, Boomsma DI, de Geus EJ. Heritability of cortisol levels: review and simultaneous analysis of twin studies. *Psychoneuroendocrinology*. 2003;28(2):121-37.
 32. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. *J Clin Endocrinol Metab*. 1998;83(1):47-54.
 33. Dhillon WS, Kong WM, Le Roux CW, Alaghband-Zadeh J, Jones J, Carter G, et al. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic--pituitary--adrenal axis. *Eur J Endocrinol*. 2002;146(2):231-5.
 34. Russell GM, Kalafatakis K, Lightman SL. The importance of biological oscillators for HPA activity and tissue glucocorticoid response: Coordinating stress and neurobehavioural adaptation. *J Neuroendocrinol*. 2014.

35. Brooke-Wavell K, Clow A, Ghazi-Noori S, Evans P, Hucklebridge F. Ultrasound measures of bone and the diurnal free cortisol cycle: a positive association with the awakening cortisol response in healthy premenopausal women. *Calcif Tissue Int.* 2002;70(6):463-8.
36. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. *Nat Neurosci.* 2004;7(8):847-54.
37. Harris A, Seckl J. Glucocorticoids, prenatal stress and the programming of disease. *Horm Behav.* 2011;59(3):279-89.
38. Sher LB, Woitge HW, Adams DJ, Gronowicz GA, Krozowski Z, Harrison JR, et al. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. *Endocrinology.* 2004;145(2):922-9.
39. Peng YM, Lei SF, Guo Y, Xiong DH, Yan H, Wang L, et al. Sex-specific association of the glucocorticoid receptor gene with extreme BMD. *J Bone Miner Res.* 2008;23(2):247-52.
40. Greendale GA, Unger JB, Rowe JW, Seeman TE. The relation between cortisol excretion and fractures in healthy older people: results from the MacArthur studies-Mac. *J Am Geriatr Soc.* 1999;47(7):799-803.
41. McTernan PG, Anderson LA, Anwar AJ, Eggo MC, Crocker J, Barnett AH, et al. Glucocorticoid regulation of p450 aromatase activity in human adipose tissue: gender and site differences. *J Clin Endocrinol Metab.* 2002;87(3):1327-36.
42. Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, et al. Sex steroid actions in male bone. *Endocr Rev.* 2014;35(6):906-60.
43. Shirtcliff EA, Allison AL, Armstrong JM, Slattery MJ, Kalin NH, Essex MJ. Longitudinal stability and developmental properties of salivary cortisol levels and circadian rhythms from childhood to adolescence. *Dev Psychobiol.* 2012;54(5):493-502.
44. Hankin BL, Badanes LS, Smolen A, Young JF. Cortisol reactivity to stress among youth: stability over time and genetic variants for stress sensitivity. *J Abnorm Psychol.* 2015;124(1):54-67.
45. Franck H, Munz M. Total body and regional bone mineral densitometry (BMD) and soft tissue measurements: correlations of BMD parameter to lumbar spine and hip. *Calcif Tissue Int.* 2000;67(2):111-5.
46. Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. *Osteoporos Int.* 1998;8(3):247-54.

Table 1 Characteristics of male and female participants at 18 years of age according to TSST response pattern

	Male				Female			
	All (n = 411)	Reactive responder (n = 260)	Anticipatory responder (n = 101)	Non- responder (n = 50)	All (n = 390)	Reactive responder (n = 200)	Anticipatory responder (n = 115)	Non- responder (n = 75)
Age, years	18.3 (0.3)	18.2 (0.2)	18.3 (0.3)	18.3 (0.3)	18.3 (0.3)	18.3 (0.3)	18.3 (0.2)	18.3 (0.3)
Height, cm	178.4 (7.0)*	178.9 (6.9)	177.8 (7.0)	177.0 (7.5)	165.9 (6.0)	165.5 (5.6)	166.4 (6.8)	166.5 (6.0)
Weight, kg	74.3 (13.6)*	74.7 (13.8)	73.1 (12.0)	74.0 (15.4)	64.1 (12.5)	65.6 (13.4)	63.9 (11.8)	60.3 (10.0) ^a
BMI, kg	23.3 (3.9)	23.3 (4.0)	23.1 (3.5)	23.6 (4.3)	23.3 (4.4)	23.9 (4.8)	23.1 (4.0)	21.8 (3.5) ^a
Current smoker, %	14.4**	11.9	17.8	20.0	8.7	5.5	11.3	13.3
Oral contraceptive use, %	-	-	-	-	41.0	38.5	41.7	46.7
BL plasma cortisol, nM	375.5 (177.1)**	324.4 (144.9)	527.1 (188.3) ^{a,b}	346.5 (140.0)	410.0 (235.4)	363.5 (210.4)	525.6 (268.4) ^{a,b}	364.6 (189.2)
BL salivary cortisol, nM	15.4 (10.3)*	12.4 (7.1)	23.1 (13.2) ^{a,b}	14.7 (9.1)	12.8 (9.3)	10.4 (5.6)	18.5 (12.8) ^{a,b}	10.6 (6.5)
Peak plasma cortisol, nM	518.0 (200.5)	534.1 (197.1)	546.5 (204.1) ^b	386.4 (159.7) ^a	524.5 (257.3)	563.9 (257.0)	538.2 (274.4) ^b	413.6 (200.4) ^a
Peak salivary cortisol, nM	20.2 (11.4)*	19.7 (10.4)	23.6 (13.3) ^{a,b}	15.7 (10.2)	16.5 (10.2)	16.8 (8.8)	18.8 (12.7) ^b	11.9 (7.4) ^a
AUC₁ plasma cortisol	-987 (11430)	6003 (8571)	-15161 (7086) ^{a,b}	-3420 (3306) ^a	-249 (11768)	6318 (9666)	-12968 (7100) ^{a,b}	-2184 (3313) ^a
AUC₁ salivary cortisol	-115.3 (626.2)	226.6 (513.4)	-900.4 (831.1) ^{a,b}	-257.0 (273.7) ^a	-110.7 (754.3)	200.1 (452.5)	-659.5 (678.7) ^{a,b}	-121.8 (285.0) ^a

Values are means (SD) unless otherwise stated. For plasma cortisol (BL, peak and AUC₁), n = 357 and 291 for males and females, respectively. *P < 0.05, **P ≤ 0.001 compared with female (Student t-test or chi-square test); ^aP < 0.05 compared with reactive responders, ^bP < 0.05 compared with non-responders in the same sex (ANOVA with Tukey post hoc test). BL: baseline; AUC₁: Area under the curve with respect to increase.

Table 2 Characteristics of male and female participants at 20 years according to TSST response pattern

	Male				Female			
	All (n = 411)	Reactive responder (n = 260)	Anticipatory responder (n = 101)	Non- responder (n = 50)	All (n = 390)	Reactive responder (n = 200)	Anticipatory responder (n = 115)	Non- responder (n = 75)
Age, years	20.1 (0.4)	20.0 (0.4)	20.1 (0.4)	20.0 (0.5)	20.0 (0.4)	20.0 (0.4)	20.0 (0.4)	20.1 (0.5)
Height, cm	178.8 (7.0)*	179.2 (6.9)	178.7 (7.3)	177.1 (7.0)	166.0 (6.2)	165.9 (6.0)	166.3 (6.8)	166.0 (6.1)
Weight, kg	76.8 (13.8)*	77.4 (14.1)	75.7 (12.9)	75.6 (14.1)	65.2 (12.7)	66.3 (13.5)	65.3 (11.8)	61.9 (11.7) ^a
BMI, kg/m²	24.0 (3.9)	24.1 (3.9)	23.7 (3.7)	24.1 (4.0)	23.6 (4.6)	24.1 (4.9)	23.6 (4.0)	22.5 (4.4) ^a
Calcium intake, mg/day	1018 (370)*	1015 (386)	1033 (347)	1001 (339)	834 (306)	830 (300)	819 (278)	864 (360)
Current smoker, %	18.0**	16.2	18.8	26.0	11.3	10.5	12.2	12.0
Alcohol intake \geq3 units/d, %	12.9*	12.3	12.9	16.0	3.3	4.0	2.6	2.7
Physical activity, %								
Low	6.7	7.3	4.5	8.1	12.6	12.4	12.0	13.9
Medium	30.9	28.8	31.8	40.5	53.4	54.3	52.0	52.8
High	62.4*	63.9	63.6	51.4	34.1	33.3	36.0	33.3
Total body BMC, g	3201 (425)**	3251 (424)	3111 (413) ^a	3123 (424)	2689 (330)	2712 (340)	2693 (319)	2623 (316)
Total body bone area, cm²	2834 (189)**	2849 (186)	2814 (192)	2798 (193)	2634 (179)	2633 (176)	2646 (184)	2623 (180)
Total body BMD, mg/cm²	1127 (107)**	1139 (107)	1103 (102) ^a	1113 (107)	1019 (83)	1028 (85)	1016 (79)	999 (85) ^a

Values are means (SD) unless otherwise stated. For calcium intake n = 362 and 365; for physical activity level n = 330 and 358 for male and female, respectively. *P < 0.05, **P \leq 0.001 compared to female (Student t-test or chi-square test); ^aP < 0.05 compared to reactive responders in the same sex (ANOVA with Tukey post hoc test).

Table 3 Regression coefficients for baseline cortisol and total body bone measures

	Model with Log [Total plasma cortisol, nM]		Model with Log [salivary cortisol, nM]		Model with [AUC ₁ total plasma cortisol/1000]		Model with [AUC ₁ salivary cortisol/1000]	
	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P
Male								
BMC, g	-71.2 (-139.0, -3.4)	0.040	-72.8 (-122.8, -22.9)	0.004	2.4 (-0.2, 5.0)	0.068	52.0 (15.4, 88.7)	0.005
Bone area, cm ²	-4.9 (-29.1, 19.3)	0.690	-13.4 (-31.2, 4.5)	0.141	0.2 (-0.7, 1.1)	0.660	1.9 (-11.3, 15.0)	0.781
BMD, mg/cm ²	-23.0 (-43.9, -2.0)	0.032	-19.4 (-35.1, -3.8)	0.015	0.8 (-0.04, 1.6)	0.061	17.3 (5.9, 28.7)	0.003
Female								
BMC, g	-28.0 (-80.9, 24.9)	0.298	1.3 (-34.1, 36.7)	0.944	1.2 (-0.9, 3.2)	0.255	7.0 (-23.8, 37.8)	0.655
Bone area, cm ²	-32.1 (-60.8, -3.5)	0.028	-4.2 (-23.2, 14.9)	0.666	0.4 (-0.7, 1.6)	0.423	1.1 (-15.5, 17.7)	0.896
BMD, mg/cm ²	1.7 (-16.3, 19.8)	0.850	1.6 (-10.7, 13.9)	0.802	0.2 (-0.5, 0.9)	0.505	1.7 (-9.0, 12.4)	0.758

AUC₁: Area under the curve with respect to increase. Other independent variables included in the models are weight, height (for BMC and bone area only) and alcohol consumption at 20 years, smoking at 18 and 20 years, and oral contraceptive use at 18 years (female only).

Table 4 Total body bone measures according to TSST response pattern

	Reactive responder	Anticipatory responder	Non-responder	P
<i>Male</i>				
N	260	101	50	
Bone mineral content, g	3233 (18)	3131 (28) ^a	3177 (40)	0.007
Bone area, cm ²	2840 (6)	2818 (10)	2834 (14)	0.196
Bone mineral density, mg/cm ²	1136 (6)	1108 (9) ^a	1118 (13)	0.020
<i>Female</i>				
N	200	115	75	
Bone mineral content, g	2697 (14)	2686 (18)	2675 (22)	0.683
Bone area, cm ²	2629 (7)	2640 (10)	2641 (12)	0.529
Bone mineral density, mg/cm ²	1023 (5)	1016 (6)	1012 (8)	0.400

Values are adjusted means (SEM), calculated using analysis of covariance (ANCOVA) adjusted for weight, height (for BMC and bone area only) and alcohol consumption at 20 years, smoking at 18 and 20 years, and oral contraceptive use at 18 years (female only). ^aP < 0.05 compared with reactive responders in the same sex (ANCOVA with Bonferroni post hoc test).

Figure legends

Figure 1 Participant disposition chart showing how the study population was derived. DXA, dual-energy x-ray absorptiometry; TSST, Trier Social Stress Test

Figure 1

